# Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery

> **NCT00758199** · PHASE4 · COMPLETED · sponsor: **Bp Consulting, Inc** · enrollment: 49 (actual)

## Conditions studied

- Cataracts

## Interventions

- **DRUG:** Bromfenac
- **DRUG:** Moxifloxacin hydrochloride
- **DRUG:** Prednisolone Acetate

## Key facts

- **NCT ID:** NCT00758199
- **Lead sponsor:** Bp Consulting, Inc
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2012-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00758199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00758199, "Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00758199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*